SEHK:2096Pharmaceuticals
Simcere (SEHK:2096) Valuation Spotlight After SIM0278 Advances to Phase II Trials for Atopic Dermatitis
Simcere Pharmaceutical Group (SEHK:2096) has kicked off Phase II clinical trials in China for SIM0278, its IL-2 mutant fusion protein targeting moderate to severe atopic dermatitis. The new study highlights advances in selective immune therapies.
See our latest analysis for Simcere Pharmaceutical Group.
Momentum has been surging for Simcere Pharmaceutical Group lately, with the stock posting a 1-day share price return of 7.52% and an 18.01% gain over the past month. Its year-to-date share...